Cerecor to Participate in Upcoming Investor Conferences
May 17 2021 - 7:00AM
Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on
becoming a leader in the development and commercialization of
treatments for rare and orphan diseases, today announced that
members of its senior management team will participate in three
upcoming virtual investor conferences.
2021 RBC Capital Markets Global Healthcare
Virtual Conference Date: Tuesday, May 18, 2021Time: 8:35 AM ET
Oppenheimer Rare & Orphan Disease
SummitDate: Friday, May 21, 20211x1 meetings only
Jefferies Virtual Healthcare ConferenceDate:
Wednesday, June 2, 2021Time: 1:00 PM ET
A live webcast of the presentation at the 2021
RBC Capital Markets Global Healthcare Virtual Conference and the
Jefferies Virtual Healthcare Conference can be accessed under the
"News/Events" page in the Investors section of the Company's
website at www.cerecor.com.
About Cerecor
Cerecor is a biopharmaceutical company focused
on becoming a leader in the development and commercialization of
treatments for rare and orphan diseases. The company is advancing
its clinical-stage pipeline of innovative therapies that address
unmet patient needs within rare and orphan diseases. The company's
rare disease pipeline includes CERC-801, CERC-802 and CERC-803,
which are in development for congenital disorders of glycosylation
and CERC-006, an oral mTORc1/c2 inhibitor in development for the
treatment of complex lymphatic malformations. The company is also
developing two monoclonal antibodies, CERC-002, and CERC-007.
CERC-002 targets the cytokine LIGHT (TNFSF14) and is in clinical
development for treatment of severe pediatric-onset Crohn's
disease, and COVID-19 acute respiratory distress syndrome. CERC-007
targets the cytokine IL-18 and is in clinical development for the
treatment of Still’s disease (adult onset Still’s disease (AOSD)
and systemic juvenile idiopathic arthritis (sJIA)), and multiple
myeloma (MM). CERC-006, 801, 802 and 803 have all received Orphan
Drug Designation and Rare Pediatric Disease Designation, which
makes all four eligible for a priority review voucher upon FDA
approval.
For more information about Cerecor, please visit
www.cerecor.com.
Forward-Looking Statements
This press release may include forward-looking
statements made pursuant to the Private Securities Litigation
Reform Act of 1995. Forward-looking statements are statements that
are not historical facts. Such forward-looking statements are
subject to significant risks and uncertainties that are subject to
change based on various factors (many of which are beyond Cerecor’s
control), which could cause actual results to differ from the
forward-looking statements. Such statements may include, without
limitation, statements with respect to Cerecor’s plans, objectives,
projections, expectations and intentions and other statements
identified by words such as “projects,” “may,” “might,” “will,”
“could,” “would,” “should,” “continue,” “seeks,” “aims,”
“predicts,” “believes,” “expects,” “anticipates,” “estimates,”
“intends,” “plans,” “potential,” or similar expressions (including
their use in the negative), or by discussions of future matters
such as: the development of product candidates or products; timing
and success of trial results and regulatory review; potential
attributes and benefits of product candidates; and other statements
that are not historical. These statements are based upon the
current beliefs and expectations of Cerecor’s management but are
subject to significant risks and uncertainties, including: drug
development costs, timing and other risks, including reliance on
investigators and enrollment of patients in clinical trials, which
might be slowed by the COVID-19 pandemic; regulatory risks;
Cerecor's cash position and the potential need for it to raise
additional capital; general economic and market risks and
uncertainties, including those caused by the COVID-19 pandemic; and
those other risks detailed in Cerecor’s filings with the Securities
and Exchange Commission. Actual results may differ from those set
forth in the forward-looking statements. Except as required by
applicable law, Cerecor expressly disclaims any obligations or
undertaking to release publicly any updates or revisions to any
forward-looking statements contained herein to reflect any change
in Cerecor’s expectations with respect thereto or any change in
events, conditions or circumstances on which any statement is
based.
For media and investor
inquiries
Chris BrinzeyWestwicke, an ICR
Companychris.brinzey@westwicke.com339-970-2843
or
Schond L. GreenwayInvestor RelationsChief
Financial OfficerCerecor Inc.sgreenway@cerecor.com610-522-6200
Cerecor (NASDAQ:CERC)
Historical Stock Chart
From Oct 2024 to Nov 2024
Cerecor (NASDAQ:CERC)
Historical Stock Chart
From Nov 2023 to Nov 2024